GO:0032729 positive regulation of type II interferon production: Immune Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032729 describes any process that activates or increases the frequency, rate, or extent of interferon-gamma (IFN-γ) production, also known as type II interferon.
• IFN-γ is a critical cytokine for innate and adaptive immunity, and its production is tightly regulated at transcriptional and post-transcriptional levels.
• Key positive regulators include cytokines such as IL-12 and IL-18, transcription factors like T-bet and STAT4, and costimulatory signals.
• Dysregulation of IFN-γ production is implicated in autoimmune diseases, chronic infections, and cancer.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of genes controlling IFN-γ production.
• Understanding GO:0032729 aids in developing immunotherapies and vaccines targeting T cell responses.
Description
Interferon-gamma (IFN-γ), also known as type II interferon, is a pleiotropic cytokine essential for host defense against pathogens and for immune surveillance. The Gene Ontology term GO:0032729, positive regulation of type II interferon production, encompasses all molecular events that enhance the synthesis and secretion of IFN-γ. This process is central to immune responses, and its dysregulation contributes to autoimmunity, chronic inflammation, and cancer. Researchers study GO:0032729 to identify therapeutic targets and understand how T cells and natural killer (NK) cells are activated. Recent advances in CRISPR gene editing allow precise manipulation of genes involved in this pathway, facilitating functional genomics and drug discovery.
positive regulation of type II interferon production At A Glance
| GO ID | GO:0032729 |
|---|---|
| GO term | positive regulation of type II interferon production |
| Ontology | biological_process |
| Synonym | activation of interferon-gamma production; positive regulation of interferon-gamma biosynthetic process; positive regulation of interferon-gamma production; positive regulation of interferon-gamma secretion; stimulation of interferon-gamma production; up regulation of interferon-gamma production; up-regulation of interferon-gamma production; upregulation of interferon-gamma production |
| Major function | Enhances the production and secretion of IFN-γ, a key cytokine for immune defense and regulation. |
| Related cytokines | IL-12, IL-18, IL-2, and type I interferons can positively regulate IFN-γ production. |
| Key transcription factors | T-bet (TBX21), STAT4, NF-κB, and AP-1 are involved in transcriptional activation of IFNG. |
| Post-transcriptional regulation | mRNA stability and microRNAs, such as ZFP36L2, modulate IFN-γ production. |
| Disease relevance | Autoimmune diseases (e.g., dermatomyositis), hypertension, and cancer. |
What Is GO:0032729?
GO:0032729 is a biological process term defined as any process that activates or increases the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon. This includes transcriptional activation, post-transcriptional stabilization, and secretion of IFN-γ.
Why Is positive regulation of type II interferon production Important in Cell Biology?
Positive regulation of type II interferon production is crucial for effective immune responses against viral and intracellular bacterial infections, and for tumor immunosurveillance. It also plays a role in autoimmune pathogenesis when overactive. Understanding this process informs vaccine design, immunotherapy, and treatment of inflammatory diseases.
• Essential for host defense against pathogens, including viruses and intracellular bacteria.
• Critical for macrophage activation and MHC class II antigen presentation.
• Drives Th1 differentiation and cell-mediated immunity.
• Implicated in autoimmune diseases such as dermatomyositis and hypertension.
• Modulates liver regeneration through immune cell crosstalk.
• Target for cancer immunotherapy to enhance anti-tumor immunity.
• Regulated by cytokines like IL-12 and IL-18, linking innate and adaptive immunity.
• Post-transcriptional control by RNA-binding proteins affects IFN-γ levels.
• Genetic variations in IFN-γ pathway genes influence disease susceptibility.
• CRISPR screening identifies novel regulators of IFN-γ production.
What Happens During positive regulation of type II interferon production?
Initiation by Cytokine Signals
In simple terms: Cytokines like IL-12 and IL-18 tell immune cells to start making IFN-γ.
Positive regulation of IFN-γ production begins when antigen-presenting cells secrete cytokines such as IL-12 and IL-18, which bind to receptors on T cells and NK cells. This triggers signaling cascades that activate transcription factors, including STAT4 and NF-κB, leading to IFNG gene transcription.
Transcriptional Activation of IFNG
In simple terms: Transcription factors turn on the IFNG gene to produce mRNA.
Activated STAT4 and T-bet (TBX21) bind to the IFNG promoter and enhancer regions, recruiting coactivators and RNA polymerase II to initiate transcription. This results in increased IFNG mRNA levels.
Post-transcriptional Stabilization
In simple terms: The mRNA for IFN-γ is protected from degradation, allowing more protein to be made.
RNA-binding proteins such as ZFP36L2 regulate the stability of IFNG mRNA. Phosphorylation of ZFP36L2 leads to its degradation, thereby stabilizing IFNG mRNA and enhancing IFN-γ production in a time-dependent manner.
Secretion and Feedback
In simple terms: The produced IFN-γ is released from the cell to act on other cells.
Newly synthesized IFN-γ is secreted via the classical secretory pathway. Secreted IFN-γ binds to its receptor (IFNGR) on target cells, activating JAK-STAT signaling and inducing IFN-γ-stimulated genes, which can further modulate the immune response.
Key Genes Involved in GO:0032729 positive regulation of type II interferon production
The following genes and proteins are key players in the positive regulation of type II interferon production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Encodes interferon-gamma, the cytokine whose production is regulated | Target for knockout/knock-in to study production and function |
| IL12A | Subunit of IL-12, a cytokine that induces IFN-γ production | Knockout models show impaired Th1 responses |
| IL12B | Subunit of IL-12 and IL-23, critical for IFN-γ induction | Polymorphisms linked to autoimmune diseases |
| IL18 | Cytokine that synergizes with IL-12 to induce IFN-γ | Knockout reduces IFN-γ in infection models |
| STAT4 | Transcription factor activated by IL-12, drives IFNG transcription | Essential for Th1 differentiation |
| TBX21 | T-bet, master transcription factor for Th1 and IFN-γ expression | Overexpression enhances IFN-γ production |
| NFKB1 | NF-κB subunit, activates IFNG transcription | Knockout impairs IFN-γ responses |
| ZFP36L2 | RNA-binding protein that destabilizes IFNG mRNA; its degradation enhances IFN-γ | Knockout increases IFN-γ production |
| IFNGR1 | Receptor for IFN-γ, mediates feedback and signaling | Mutations cause immunodeficiency |
| IFNGR2 | Accessory receptor subunit for IFN-γ | Defects lead to impaired IFN-γ signaling |
| JAK1 | Kinase activated by IFN-γ receptor, downstream signaling | Knockout abolishes IFN-γ responses |
| JAK2 | Kinase activated by IFN-γ receptor, downstream signaling | Essential for STAT1 activation |
| STAT1 | Transcription factor mediating IFN-γ signaling | Knockout impairs IFN-γ-induced gene expression |
| IL2 | Cytokine that can enhance IFN-γ production in T cells | Used in T cell activation protocols |
| IL15 | Cytokine that promotes NK cell IFN-γ production | Knockout reduces NK cell function |
| CD28 | Costimulatory receptor on T cells, enhances IFN-γ production | Blockade reduces IFN-γ |
| MHC2TA | Regulates MHC class II expression, influences IFN-γ production | Polymorphisms affect cytokine levels |
How Is positive regulation of type II interferon production Regulated?
The positive regulation of type II interferon production is controlled at multiple levels. Transcriptional regulation involves transcription factors such as T-bet, STAT4, and NF-κB, which are activated by cytokine receptors and costimulatory molecules. Post-transcriptional mechanisms include mRNA stability modulated by RNA-binding proteins like ZFP36L2. Additionally, epigenetic modifications and microRNAs can influence IFNG expression. Feedback inhibition by IFN-γ itself or by cytokines like IL-10 can limit excessive production.
positive regulation of type II interferon production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNG | Autoimmunity, infection susceptibility | Knockout mice, human T cell lines |
| IL12B | Psoriasis, inflammatory bowel disease | Knock-in of risk alleles |
| ZFP36L2 | Immune dysregulation | Knockout T cells |
| STAT4 | Rheumatoid arthritis, lupus | Overexpression in T cells |
| IFNGR1 | Mycobacterial infections | Patient-derived iPSCs |
Autoimmune and Inflammatory Diseases
Dysregulated IFN-γ production contributes to autoimmune diseases such as dermatomyositis with anti-MDA5 antibodies, where IFN-γ is an overlooked cytokine driving pathology. In hypertension, IFN-γ contributes to immune mechanisms of vascular dysfunction. Targeting positive regulators of IFN-γ production may offer therapeutic benefits.
Infectious Diseases
IFN-γ is critical for defense against intracellular pathogens. Positive regulation of its production is essential for clearing infections; deficiencies lead to susceptibility to mycobacterial and viral infections. Understanding regulators can inform vaccine adjuvants.
Cancer
IFN-γ enhances anti-tumor immunity by promoting antigen presentation and activating cytotoxic T cells. Positive regulators of IFN-γ production are targets for cancer immunotherapy. Conversely, chronic IFN-γ signaling can promote immune evasion.
Liver Regeneration
B cell-derived acetylcholine promotes liver regeneration by regulating Kupffer cell and hepatic CD8+ T cell function, in part through IFN-γ modulation. This highlights tissue-specific roles of IFN-γ regulation.
From positive regulation of type II interferon production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate IFN-γ production? | CRISPR knockout in primary T cells or Jurkat cells |
| Does SNP rsXXX affect IFN-γ levels? | Point mutation knock-in via CRISPR |
| Can a tag help track IFN-γ secretion? | Knock-in of fluorescent tag at IFNG locus |
| Does overexpression of gene Y enhance IFN-γ? | CRISPR activation or lentiviral overexpression |
| What is the effect of a disease-associated mutation? | Knock-in of mutant allele in cell lines |
| Can we screen for novel regulators? | Genome-wide CRISPR library screening |
How to Study the positive regulation of type II interferon production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | IFNG mRNA levels and transcriptome | Identify transcriptional regulators |
| ELISA | Secreted IFN-γ protein | Quantify cytokine production |
| Flow cytometry | Intracellular IFN-γ and surface markers | Analyze T cell subsets |
| CRISPR knockout | Gene function loss | Validate positive regulators |
| CRISPR activation | Gene overexpression | Enhance IFN-γ production |
| Reporter assays | Real-time IFNG expression | Live-cell imaging |
| Proteomics | Protein interactions and signaling | Map pathways |
| ATAC-seq | Chromatin accessibility at IFNG locus | Study epigenetic regulation |
Transcriptional Profiling
RNA-seq and qPCR measure IFNG mRNA levels after stimulation. These methods identify transcriptional changes in response to positive regulators.
Protein Detection
ELISA and flow cytometry quantify secreted and intracellular IFN-γ protein. These are standard for assessing production levels.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens identify genes that positively or negatively regulate IFN-γ production. Hits are validated individually.
Imaging and Reporter Assays
Reporter cell lines with fluorescent or luminescent tags at the IFNG locus allow real-time monitoring of IFN-γ expression in live cells.
How CRISPR Can Be Used to Study GO:0032729 positive regulation of type II interferon production
Knockout
CRISPR knockout of candidate genes in T cells or NK cells can determine whether they are required for IFN-γ production. For example, knockout of ZFP36L2 increases IFN-γ production, confirming its role as a negative regulator.
Point Mutation
Introducing disease-associated SNPs or phospho-mimetic mutations via CRISPR base editing or HDR allows study of their impact on IFN-γ regulation. This is useful for fine-mapping regulatory variants.
Knock-in
Knock-in of fluorescent reporters (e.g., GFP) at the IFNG locus enables tracking of IFN-γ-producing cells. Knock-in of epitope tags facilitates protein purification and interaction studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of candidate genes can test sufficiency for enhancing IFN-γ production. This complements knockout studies.
How EDITGENE Supports positive regulation of type II interferon production Research
Researchers studying positive regulation of type II interferon production-related genes often need to determine whether a candidate gene is causally involved in IFN-γ regulation. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of type II interferon production research.
Frequently Asked Questions About positive regulation of type II interferon production
What is GO:0032729?
GO:0032729 is a Gene Ontology term for positive regulation of type II interferon production, describing processes that increase the production of interferon-gamma.
What genes are involved in positive regulation of type II interferon production?
Key genes include IFNG, IL12A, IL12B, IL18, STAT4, TBX21, NFKB1, and ZFP36L2.
How is type II interferon production regulated?
It is regulated transcriptionally by factors like T-bet and STAT4, and post-transcriptionally by RNA-binding proteins such as ZFP36L2.
What diseases are associated with dysregulated IFN-γ production?
Autoimmune diseases like dermatomyositis, hypertension, and certain infections.
What methods are used to study positive regulation of type II interferon production?
RNA-seq, ELISA, flow cytometry, CRISPR screens, and reporter assays.
Can CRISPR be used to study IFN-γ regulation?
Yes, CRISPR knockout, knock-in, and activation are powerful tools to dissect the pathway.
What is the role of ZFP36L2 in IFN-γ production?
ZFP36L2 destabilizes IFNG mRNA; its degradation enhances IFN-γ production in a time-dependent manner.
How does IL-12 regulate IFN-γ production?
IL-12 activates STAT4, which induces IFNG transcription and Th1 differentiation.
What is the difference between type I and type II interferon?
Type I interferons (IFN-α/β) are primarily antiviral, while type II interferon (IFN-γ) is a key immune-regulatory cytokine.
How can I model IFN-γ-related diseases with CRISPR?
EDITGENE offers knockout, knock-in, and overexpression models to study disease-associated mutations and pathways.
Conclusion
GO:0032729, positive regulation of type II interferon production, is a central biological process in immunity and disease. Understanding its regulators offers insights into autoimmune diseases, infections, and cancer. CRISPR-based tools from EDITGENE enable precise functional studies to accelerate discovery.
References
- 1. Modares NF et al.. 2025. B cell-derived acetylcholine promotes liver regeneration by regulating Kupffer cell and hepatic CD8(+) T cell function.. Immunity 58(5):1201-1216.e7 PMID: 40286791
- 2. Zandhuis ND et al.. 2024. Regulation of IFN-γ production by ZFP36L2 in T cells is time-dependent.. Eur J Immunol 54(10):e2451018 PMID: 38980256
- 3. Billiau A et al.. 2009. Interferon-gamma: a historical perspective.. Cytokine Growth Factor Rev 20(2):97-113 PMID: 19268625
- 5. Estes DM et al.. 2002. Type 1 and type 2 responses in regulation of Ig isotype expression in cattle.. Vet Immunol Immunopathol 90(1-2):1-10 PMID: 12406650
- 6. Benson LN et al.. 2022. IFN-γ Contributes to the Immune Mechanisms of Hypertension.. Kidney360 3(12):2164-2173 PMID: 36591357
- 7. Thuner J et al.. 2023. IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies.. Autoimmun Rev 22(10):103420 PMID: 37625674
- 8. Caruso C et al.. 1996. Major histocompatibility complex regulation of cytokine production.. J Interferon Cytokine Res 16(12):983-8 PMID: 8973998
